Report Sections

See All Reports

  • HP:0000729: Autistic behavior
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000729: Autistic behavior

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (42)


    Name (Synonyms) Correlation
    drug758 COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection Wiki 0.38
    drug754 COVID-19 RT-PCR Wiki 0.31
    drug2603 Non-convalescent fresh frozen plasma (Standard plasma) Wiki 0.27
    Name (Synonyms) Correlation
    drug3848 Symptoms questionnare Wiki 0.27
    drug750 COVID-19 PCR and Serology Wiki 0.27
    drug757 COVID-19 Swab Wiki 0.27
    drug751 COVID-19 PCR and serology testing Wiki 0.27
    drug1088 Counseling Services Alone Wiki 0.27
    drug4287 Wearable Medical Device (Empatica E4) Wiki 0.27
    drug3607 Sham Attention Training Wiki 0.27
    drug1073 Cord Tissue Mesenchymal Stromal Cells Wiki 0.27
    drug3157 Pulse Oximeter Wiki 0.27
    drug747 COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) Wiki 0.27
    drug749 COVID-19 PCR Swab Wiki 0.27
    drug1375 Emotional Support Plan Wiki 0.27
    drug4083 Treatment As Usual Wiki 0.27
    drug763 COVID-19 convalescent hyperimmune plasma Wiki 0.27
    drug141 ASSIST Wiki 0.27
    drug2816 Parents and Infants Engaged Wiki 0.27
    drug28 12-week FMS Intervention Wiki 0.27
    drug760 COVID-19 antibodies testing Wiki 0.27
    drug762 COVID-19 barrier box Wiki 0.27
    drug843 Cannabidivarin Wiki 0.27
    drug4561 lung ultrasound Wiki 0.27
    drug1351 Elaborative Reminiscence (ER) Wiki 0.27
    drug761 COVID-19 antibody point of care test kit Wiki 0.27
    drug1661 Group Social ABCs Wiki 0.27
    drug2943 Placebo Infusion Wiki 0.27
    drug3078 Present Tense Talk (PTT) Wiki 0.27
    drug3881 TEACCH School Transition to Employment and Postsecondary Education (T-STEP) Wiki 0.27
    drug1994 Interview by psychologists Wiki 0.27
    drug3353 Responsive training with video feedback Wiki 0.27
    drug395 Attention Training Program Wiki 0.27
    drug3653 Social ABCs Wiki 0.27
    drug3232 RO6953958 Wiki 0.27
    drug1148 Daily Monitoring Wiki 0.27
    drug2894 Physical Activities & Activity Booklets Wiki 0.27
    drug3352 Responsive training with no video feedback Wiki 0.27
    drug755 COVID-19 Serology Wiki 0.19
    drug2292 Matched Placebo Wiki 0.19
    drug764 COVID-19 convalescent plasma Wiki 0.12
    drug2916 Placebo Wiki 0.01

    Correlated MeSH Terms (10)


    Name (Synonyms) Correlation
    D000067877 Autism Spectrum Disorder NIH 1.00
    D001321 Autistic Disorder NIH 0.89
    D002659 Child Development Disorders, Pervasive NIH 0.65
    Name (Synonyms) Correlation
    D065886 Neurodevelopmental Disorders NIH 0.38
    D001289 Attention Deficit Disorder with Hyperactivity NIH 0.27
    D004194 Disease NIH 0.21
    D006948 Hyperkinesis NIH 0.19
    D002658 Developmental Disabilities NIH 0.15
    D001523 Mental Disorders NIH 0.05
    D013315 Stress, Psychological NIH 0.05

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0000717 Autism HPO 0.89
    HP:0007018 Attention deficit hyperactivity disorder HPO 0.27
    HP:0002487 Hyperkinetic movements HPO 0.19

    Clinical Trials

    Navigate: Correlations   HPO

    There are 14 clinical trials


    1 Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

    This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

    NCT03202303
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Drug: Cannabidivarin
    2. Drug: Matched Placebo
    MeSH:Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Change in ABC-I from Baseline to Endpoint

    Measure: Aberrant Behavior Checklist-Irritability Subscale (ABC-I)

    Time: Change in ABC-I from Baseline to Week 12 (Change over 12 weeks)

    Secondary Outcomes

    Description: Change in RBS-R from Baseline to Endpoint

    Measure: Repetitive Behavior Scale-Revised (RBS-R)

    Time: Change in RBS-R from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in ABC-SW from Baseline to Endpoint

    Measure: Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW)

    Time: Change in ABC-SW from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in PedsQL from Baseline to Endpoint

    Measure: Pediatric Quality of Life Inventory (PedsQL) Family Impact Module

    Time: Change in PedsQL from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in Vineland-3 from Baseline to Endpoint

    Measure: Vineland Adaptive Behavior Scale-3 (Vineland 3)

    Time: Change in Vineland-3 from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in CGI-I from Baseline to Endpoint

    Measure: Clinical Global Impressions-Improvement (CGI-I)

    Time: Change in CGI-I from Baseline to Week 12 (Change over 12 weeks)

    Description: The MERS-R is designed to assess three domains of rigid behavior in children and adults with ASD: 1. Behavioral Rigidity (e.g., insistence on sameness, things must be done in his/her way, etc.) 2. Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.) 3. Protest (in response to deviation from rigidity; e.g., verbal objection, tantrum, physical aggression).

    Measure: Montefiore Einstein Rigidity Scale-Revised (MERS-R)

    Time: Change in MERS-R from Baseline to Week 12 (Change over 12 weeks)
    2 Evaluation of Social ABCs With Attention Training Intervention for Toddlers With Autism

    The Social ABCs is an evidence-based, developmentally informed, caregiver-mediated behavioural intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behaviour Analysis), and responsive parenting. The two key targets of this program are functional verbal communication and positive caregiver-child affect sharing. This intervention takes place in the context of play and daily routines, and in all contexts is made to be fun, natural and motivating for the child. In both a pilot study and a recently completed randomized control trial, toddlers whose caregivers received training in the Social ABCs intervention showed significant gains in early language development (both responsivity and initiations), increased child smiling (mediated by parent smiling), and a trend toward increased social orienting (one important manifestation of social attention). Despite the social-communication benefits demonstrated through the Social ABCs, the research team is also motivated to foster the attentional abilities of toddlers with emerging ASD in response to compelling evidence that early attentional control abilities may play a central role in the emergence of ASD. Based on this knowledge, the current study targets not only social-communication challenges and affect sharing (as per the existing Social ABCs intervention), but also attentional control in toddlers with suspected or confirmed ASD. Using a structured, computerized attention-training protocol, this RCT evaluates the impact of supplementing the standard Social ABCs intervention with pre-intervention attentional control training.

    NCT03215394
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Behavioral: Attention Training Program
    2. Behavioral: Social ABCs
    3. Other: Treatment As Usual
    4. Behavioral: Sham Attention Training
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Reaction time in Gap-Overlap task (milliseconds)

    Measure: Improved Attentional Flexibility

    Time: Week 1 (baseline) and Week 6

    Description: Percentage of correct trials in a computer-based attention task (%)

    Measure: Improved Attentional Control

    Time: Week 1 (baseline) and Week 6

    Description: Percentage of intervals in which child is oriented to caregiver (%)

    Measure: Increased Social Orienting to Parent

    Time: Week 1 (baseline), Week 6, Week 18, and Week 30

    Description: Percentage of intervals in which caregiver and child are smiling together (%)

    Measure: Increased Child Smiling

    Time: Week 1 (baseline), Week 6, Week 18, and Week 30

    Description: Gains in proportion of appropriate child vocal responses, following a caregiver prompt (reported as percentage).

    Measure: Increased Child Responsivity to Parent Prompt

    Time: Week 1 (baseline), Week 6, Week 18, and Week 30

    Secondary Outcomes

    Description: Percentage of intervals during which parents demonstrate appropriate use of the Social ABCs techniques (%)

    Measure: Parent Fidelity of Implementation

    Time: Week 6, Week 18, and Week 30

    Description: Standard score on the Mullen Early Learning Scale (SS)

    Measure: Receptive Language

    Time: Week 0 and Week 30

    Description: Standard score on the Mullen Early Learning Scale (SS)

    Measure: Expressive Language

    Time: Week 0 and Week 30

    Description: Frequency of joint attentions bids on the Mini Early Social Communication (#)Scales

    Measure: Joint Attention

    Time: Week 0 and Week 30
    3 Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders

    This study entails a "proof of concept" evaluation of a novel intervention, Parents and Infants Engaged (PIE), for prodromal infants at-risk for neurodevelopmental disorders (NDs). The objectives of the current study are to examine whether the PIE intervention (a) transforms parent-infant transactions over time as intended, thereby facilitating increases in the time infants spend in joint engagement with their parents, and (b) is associated with improved social-communication functioning and positive changes in indices of autonomic self-regulation in infants at-risk for NDs.

    NCT03388294
    Conditions
    1. Autism Spectrum Disorder
    2. Neurodevelopmental Disorders
    Interventions
    1. Behavioral: Parents and Infants Engaged
    MeSH:Disease Autism Spectrum Disorder Neurodevelopmental Disorders
    HPO:Autistic behavior

    Primary Outcomes

    Description: This system entails continuous coding of infants' attention engagement into one of 6 mutually exclusive states: unengaged, onlooking, object engaged, person-engaged, supported joint engagement, and coordinated joint engagement. Due to the importance of the construct of engagement to our PIE theory of change, the total percent of time in joint engagement (supported + coordinated) will serve as the most proximal intervention outcome (i.e., changes expected at Posttest-1). Recent studies with children with NDs have shown that the coding system is sensitive to change in joint engagement after relatively short interventions.

    Measure: Change in Parent Child Engagement Coding from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: This system entails continuous coding of infants' attention engagement into one of 6 mutually exclusive states: unengaged, onlooking, object engaged, person-engaged, supported joint engagement, and coordinated joint engagement. Due to the importance of the construct of engagement to our PIE theory of change, the total percent of time in joint engagement (supported + coordinated) will serve as the most proximal intervention outcome (i.e., changes expected at Posttest-1). Recent studies with children with NDs have shown that the coding system is sensitive to change in joint engagement after relatively short interventions.

    Measure: Change in Parent Child Engagement Coding from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Secondary Outcomes

    Description: The MSEL is a standardized developmental assessment for children birth to 58 months, frequently used in studies of children with NDs, and comprised of 4 scales: Fine Motor, Visual Reception, Receptive Language, and Expressive Language. The investigators will administer only the Receptive and Expressive Language subscales of the MSEL at the second posttest and the first follow up assessment. To be eligible for the intervention portion of the study, children have to score at least 1 s.d. below the mean on either the Receptive or Expressive Language subscale of the MSEL. The investigators will report t scores (Mean = 50, SD = 10)and the standardized total Early Learning Composite (Mean = 100, SD = 15). Higher scores indicate greater developmental skills.

    Measure: Change in Mullen Scales of Early Learning Receptive Language T-Scores from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: The MSEL is a standardized developmental assessment for children birth to 58 months, frequently used in studies of children with NDs, and comprised of 4 scales: Fine Motor, Visual Reception, Receptive Language, and Expressive Language. The investigators will administer only the Receptive and Expressive Language subscales of the MSEL at the second posttest and the first follow up assessment. To be eligible for the intervention portion of the study, children have to score at least 1 s.d. below the mean on either the Receptive or Expressive Language subscale of the MSEL. The investigators will report t scores (Mean = 50, SD = 10)and the standardized total Early Learning Composite (Mean = 100, SD = 15). Higher scores indicate greater developmental skills.

    Measure: Change in Mullen Scales of Early Learning Expressive Language T-scores from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: A play-based assessment used to measure children's approach-avoidance to novel sensory toys (i.e., hyper-reactivity) and orienting responses (i.e., hypo-reactivity) across three sensory modalities (auditory, visual, tactile). The investigators will report a mean score for Hypo (range = 1-5), Hyper (range = 1-5) sensory subscales. Higher scores indicate greater sensory differences in that domain (e.g. a high hypo domain score would indicate more hyposensitive reactions to sensory stimuli seen in the child).

    Measure: Change in Sensory Processing Assessment for Young Children from Pretest to Posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: A treatment response measure of social communication behaviors and other behaviors associated with autism spectrum disorder (ASD). Administration of the BOSCC involves a 12-minute video recorded interaction between an examiner and a young child using two standard sets of toys and play with bubbles. Behaviors are coded from video. Total score range is 16-80. Higher scores indicate more typical social communication skills, lower scores indicate poorer skills.

    Measure: Change in The Behavioral Observation of Social Communication Change (BOSCC) from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Designed to measure the extent to which children will follow attentional cues of the examiner. Six prompts for attention following are embedded into the larger study protocol. Items are scored dichotomously as yes "1" or no "0".Total score range is 0-6. Higher scores indicate more typical responses to bids for joint attention.

    Measure: Change in The Attention Following Protocol (AF Protocol) from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: A parent report measure of children's expressive communication skills, such as vocabulary and pre-grammar abilities. The Words and Gestures (toddler) form will be used. Total words and gestures endorsed by parents will be reported. Greater words and gestures reported indicates larger expressive vocabulary.

    Measure: Baseline expressive communication level: The MacArthur-Bates Communicative Development Inventory

    Time: Baseline

    Description: A 43 item parent questionnaire that asks about the child's responses to various sensory stimuli in the context of functional activities and daily routines in the child's environment. It also documents strategies parents use to respond to their child's behaviors. Hyper and Hypo mean domain scores will be reported (range = 1-5). Greater domain scores indicate a greater presence of that type of sensory response.

    Measure: Change in The Sensory Experiences Questionnaire version 2.1 from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: A 43 item parent questionnaire that asks about the child's responses to various sensory stimuli in the context of functional activities and daily routines in the child's environment. It also documents strategies parents use to respond to their child's behaviors. Hyper and Hypo mean domain scores will be reported (range = 1-5). Greater domain scores indicate a greater presence of that type of sensory response.

    Measure: Change in The Sensory Experiences Questionnaire version 2.1 from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: The Parental Stress Scale is a brief, 18-item scale designed to assess parent stress in nonclinical or clinical populations. It has acceptable levels of internal consistency (coefficient α = .83) and test-retest reliability (r = .81 over 6 weeks). It has good concurrent validity with the widely used Parent StressIndex (r =.75), which is a longer, more intrusive measure. A total score will be reported (range = 18-90).

    Measure: Baseline level of parent stress: Parental Stress Scale

    Time: Baseline

    Description: RSA levels will be collected using a standard protocol while the child is seated in a high chair exposed to social and non-social stimuli.

    Measure: Change in Respiratory sinus arrhythmia from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Skin conductance levels will be collected using a standard protocol while the child is seated in a high chair exposed to social and non-social stimuli.

    Measure: Change in skin conductance levels from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child prelinguistic communication cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Prelinguistic Communication Cues from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child prelinguistic communication cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Prelinguistic Communication Cues from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child sensory reactivity cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Sensory Reactivity Cues from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child sensory reactivity cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Sensory Reactivity Cues from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)
    4 Group Social ABCs: Early Intervention for Toddlers With Suspected ASD

    The Social ABCs is an evidence-based, developmentally informed, caregiver-mediated behavioural intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behavioural Analysis), and responsive parenting. The two key targets of this program are functional verbal communication and positive caregiver-child affect sharing. This intervention takes place in the context of play and daily routines, and in all contexts is made to be fun. In both a pilot study and a recently completed randomized control trial, toddlers whose caregivers received training in the Social ABCs intervention showed significant gains in early language development (both responsivity and initiations), increased child smiling (mediated by parent smiling), and a trend toward increased social orienting (one important manifestation of social attention). In an effort to make the Social ABCs more feasible for community service providers to provide this intervention to higher number families, an abbreviated version of the Social ABCs intervention is being offered in a mixed group/individual format in a clinic setting. The primary goal of this pilot project is to assess feasibility of this abbreviated program in the novel format and setting. The secondary goal is to train clinical service providers to facilitate this intervention, thus introducing the program into community practice.

    NCT03499262
    Conditions
    1. Autism Spectrum Disorder
    2. Autism
    Interventions
    1. Behavioral: Group Social ABCs
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Change in proportion of appropriate child vocal responses following a caregiver prompt in 10-minute video observation

    Measure: Vocal Responsivity

    Time: Baseline, Week 6

    Secondary Outcomes

    Description: Change in rate of appropriate child-initiated vocalizations (Initiations); number per minute

    Measure: Vocal Initiations

    Time: Baseline, Week 6

    Description: Change in percentage of intervals with instances of social orienting (child looking at parent) per 10-minute video observation

    Measure: Social Orienting

    Time: Baseline, Week 6

    Description: Change in percent of correct strategy implementation by parents (Fidelity) per 10-minute video observation

    Measure: Caregiver Fidelity of Implementation

    Time: Baseline, Week 6
    5 A Phase II Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder

    The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).

    NCT04089579
    Conditions
    1. Autism
    2. Autism Spectrum Disorder
    Interventions
    1. Biological: Cord Tissue Mesenchymal Stromal Cells
    2. Other: Placebo Infusion
    MeSH:Disease Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: The primary outcome measure is the mean of the change on the Socialization and Communication Subscale Standard Scores on the Vineland Adaptive Behavior Scales (VABS-3). The primary endpoint is the change on this outcome measure from baseline to six months.

    Measure: Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales

    Time: Baseline, 6 months

    Secondary Outcomes

    Description: Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score

    Measure: Change in VABS-3 Socialization Standard Score

    Time: Baseline, 6 months

    Description: Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score

    Measure: Change in VABS-3 Communication Standard Score

    Time: Baseline, 6 months

    Description: Clinical Global Impression- Severity Scale

    Measure: Change in CGI-Severity score

    Time: Baseline, 6 months

    Description: Clinical Global Impression- Impression

    Measure: CGI-Intervention score

    Time: Baseline, 6 months

    Description: Pediatric Quality of Life Scale

    Measure: Change in the Pediatric Quality of Life Scale

    Time: Baseline, 6 months

    Other Outcomes

    Description: Assess for infusion reactions

    Measure: Incidence and severity of infusion reactions

    Time: Baseline, 6 months

    Description: Assess for infections directly related to the study product infusions

    Measure: Incidence and severity of product-related infections

    Time: Baseline, 6 months

    Description: Assess for anti-HLA antibodies

    Measure: Evidence of formation of anti-HLA antibodies

    Time: Baseline, 6 months, 12 months

    Description: Assess for signs and symptoms of graft versus host disease

    Measure: Incidence and severity of graft versus host disease

    Time: 6 months, 12 months

    Description: Assess for study related and unexpected adverse events

    Measure: Incidence and severity of unexpected adverse events related to the study product

    Time: Baseline, 6 months, 12 months
    6 Project ASSIST: Advocating for Supports to Improve Service Transitions

    This is a randomized intervention study to test and develop the national curriculum of a parent intervention training targeting parent's ability for advocate for services to improve the transition to adulthood for their youth with autism spectrum disorder (ASD). UPDATE regarding COVID-19: The current intervention has been paused until it is safe to meet as a group again. We are still recruiting participants for cohort 2 (in TN and IL) and Cohort 1 and 2 (in WI), as the plan is to resume the intervention as soon as the situation allows and to keep the future scheduled interventions happening in the Fall of 2020, Fall of 2021 and Winter of 2022. For the baseline data collection visit, we have moved to remote data collection for all measures except the psychological testing with the youth - meaning that families will be able to partially complete baseline data via teleconference and/or phone calls and online surveys. In-person visits to complete the psychological testing with the youth will be scheduled in the future when it is safe to meet face to face.

    NCT04173663
    Conditions
    1. Autism Spectrum Disorder
    2. Autism
    Interventions
    1. Behavioral: ASSIST
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Examine whether ASSIST participation increases the intervention target of parental knowledge about adult service systems. A questionnaire created by the researchers (based on a measure developed to evaluate the VAP-T, Burke, Goldman, Hart, & Hodapp, 2016) will be used to measure parental knowledge about adult services. The questionnaire consists of 22 multiple-choice questions asking for factual information about adult disability services and the adult disability service system. The total score can range from 0 to 22. Higher scores indicate greater knowledge of the adult disability service system.

    Measure: Change in Parental Knowledge about adult services questionnaire

    Time: Baseline to initial follow-up (3 months after the intervention starts)

    Description: Examine whether ASSIST participation increases the intervention target of parental empowerment measured using the Family Empowerment Scale (FES; Koren, DeChillo, & Friesen, 1992). The 34-item questionnaire measures the extent to which parents feel empowered across three dimensions: family, the service system; and the larger community and political environment. Items are rated on a 5-point Likert Scale from 1= not at all true to 5 = very true. The total score can range from 34 to 170, with higher scores indicating greater empowerment.

    Measure: Change in Parental Empowerment Scale

    Time: Baseline to initial follow-up (3 months after the intervention starts)

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy skills measured by the Advocacy Skills and Comfort Scale (ASC; Burke, Goldman, Hart, & Hodapp, 2016). The 10-item measure assesses the degree to which parents feel comfortable and skilled in advocating for their offspring with ASD. Response options range from 1 = not at all to 5 = excellent. The total score can range from 10 to 50, with higher scores indicating more skills/comfort in advocating for their offspring.

    Measure: Change in Advocacy Skills and Comfort Scale

    Time: Baseline to initial follow-up (3 months after the intervention starts)

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in social participation for youth with ASD. Questions developed to measure social participation (Taylor, Adams, & Bishop, 2016) will be used to measure the social participation achievements of the youth participants before and after ASSIST per parent-report. This measure consists of 10 items with a 5-point Likert scale ranging from 0 = Less than yearly or never to 4 = Several times a week. The total score can range from 0 to 40, with higher scores indicating greater social participation for the youth with ASD.

    Measure: Social Participation Youth Outcomes

    Time: 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 12 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy activities, measured using the Advocacy Activities measure (Taylor, Hodapp, Burke, Waitz-Kudla, & Rabideau, 2017).The 16-item instrument measures how frequently parents spend time in advocacy activities for the son/daughter with ASD. The response options range from 1 = not at all to 4 = very often. The total score can range from 16 to 64, with higher scores indicating greater parent participation in advocacy activities.

    Measure: Change in Advocacy Activities Scale

    Time: Baseline to 12-month post-intervention

    Secondary Outcomes

    Description: Examine whether ASSIST participation increases the intervention target of parental knowledge about adult service systems. A questionnaire created by the researchers (based on a measure developed to evaluate the VAP-T, Burke, Goldman, Hart, & Hodapp, 2016) will be used to measure parental knowledge about adult services. The questionnaire consists of 22 multiple-choice questions asking for factual information about adult disability services and the adult disability service system. The total score can range from 0 to 22. Higher scores indicate greater knowledge of the adult disability service system.

    Measure: Change in Parental Knowledge about adult services questionnaire

    Time: Baseline to 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parental knowledge about adult service systems. A questionnaire created by the researchers (based on a measure developed to evaluate the VAP-T, Burke, Goldman, Hart, & Hodapp, 2016) will be used to measure parental knowledge about adult services. The questionnaire consists of 22 multiple-choice questions asking for factual information about adult disability services and the adult disability service system. The total score can range from 0 to 22. Higher scores indicate greater knowledge of the adult disability service system.

    Measure: Change in Parental Knowledge about adult services questionnaire

    Time: Baseline to 18-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parental empowerment measured using the Family Empowerment Scale (FES; Koren, DeChillo, & Friesen, 1992). The 34-item questionnaire measures the extent to which parents feel empowered across three dimensions: family, the service system; and the larger community and political environment. Items are rated on a 5-point Likert Scale from 1= not at all true to 5 = very true. The total score can range from 34 to 170, with higher scores indicating greater empowerment.

    Measure: Change in Parental Empowerment Scale

    Time: Baseline to 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parental empowerment measured using the Family Empowerment Scale (FES; Koren, DeChillo, & Friesen, 1992). The 34-item questionnaire measures the extent to which parents feel empowered across three dimensions: family, the service system; and the larger community and political environment. Items are rated on a 5-point Likert Scale from 1= not at all true to 5 = very true. The total score can range from 34 to 170, with higher scores indicating greater empowerment.

    Measure: Change in Parental Empowerment Scale

    Time: Baseline to 18-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy skills measured by the Advocacy Skills and Comfort Scale (ASC; Burke, Goldman, Hart, & Hodapp, 2016). The 10-item measure assesses the degree to which parents feel comfortable and skilled in advocating for their offspring with ASD. Response options range from 1 = not at all to 5 = excellent. The total score can range from 10 to 50, with higher scores indicating more skills/comfort in advocating for their offspring.

    Measure: Change in Advocacy Skills and Comfort Scale

    Time: Baseline to 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy skills measured by the Advocacy Skills and Comfort Scale (ASC; Burke, Goldman, Hart, & Hodapp, 2016). The 10-item measure assesses the degree to which parents feel comfortable and skilled in advocating for their offspring with ASD. Response options range from 1 = not at all to 5 = excellent. The total score can range from 10 to 50, with higher scores indicating more skills/comfort in advocating for their offspring.

    Measure: Change in Advocacy Skills and Comfort Scale

    Time: Baseline to 18-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in social participation for youth with ASD. Questions developed to measure social participation (Taylor, Adams, & Bishop, 2016) will be used to measure the social participation achievements of the youth participants before and after ASSIST per parent-report. This measure consists of 10 items with a 5-point Likert scale ranging from 0 = Less than yearly or never to 4 = Several times a week. The total score can range from 0 to 40, with higher scores indicating greater social participation for the youth with ASD.

    Measure: Social Participation Youth Outcomes

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in social participation for youth with ASD. Questions developed to measure social participation (Taylor, Adams, & Bishop, 2016) will be used to measure the social participation achievements of the youth participants before and after ASSIST per parent-report. This measure consists of 10 items with a 5-point Likert scale ranging from 0 = Less than yearly or never to 4 = Several times a week. The total score can range from 0 to 40, with higher scores indicating greater social participation for the youth with ASD.

    Measure: Social Participation Youth Outcomes

    Time: 30-month post-intervention

    Description: The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 6 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 24 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 30 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: 30-month post-intervention

    Description: The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before ASSIST. The investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 30-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy activities, measured using the Advocacy Activities measure (Taylor, Hodapp, Burke, Waitz-Kudla, & Rabideau, 2017).The 16-item instrument measures how frequently parents spend time in advocacy activities for the son/daughter with ASD. The response options range from 1 = not at all to 4 = very often. The total score can range from 16 to 64, with higher scores indicating greater parent participation in advocacy activities.

    Measure: Change in Advocacy Activities Scale

    Time: Baseline to 30-month post-intervention
    7 Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak

    In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).

    NCT04416360
    Conditions
    1. Autism Spectrum Disorder
    2. Attention-deficit Hyperactivity Disorder
    Interventions
    1. Other: Interview by psychologists
    MeSH:Hyperkinesis Disease Autistic Disorder Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Attention deficit hyperactivity disorder Autism Autistic behavior Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.

    Measure: Interview of the parents : contextual data

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 1 month

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 3 months

    Description: Data relating to disease and management of care. Experience of the referring caregiver.

    Measure: Interview of the referring caregiver : data relating to disease and management of care

    Time: 3 months
    8 Brain Imaging and Infant Development

    The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.

    NCT04443179
    Conditions
    1. Autism Spectrum Disorder
    2. Attention Deficit Hyperactivity Disorder
    3. Neurodevelopmental Conditions
    4. COVID-19
    MeSH:Disease Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder
    HPO:Attention deficit hyperactivity disorder Autistic behavior

    Primary Outcomes

    Measure: Neurodevelopmental Outcomes

    Time: 3-4 years of age
    9 ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19 (Coronavirus Disease)

    The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a brief, telehealth intervention (the Emotional Support Plan), intended to support autistic adults to cope with their negative emotions during and/or after the COVID-19 pandemic. The first objective is to develop and refine a brief telehealth-delivered treatment, the Emotional Support Plan (ESP), to help promote adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic. The second objective is to assess the feasibility and effectiveness of the ESP to support autistic adults to implement emotion regulation strategies during periods of acute distress. The last objective is to yield preliminary data to apply for extramural grants to validate these methods to monitor and support mental health of autistic adults during key transitions (e.g., starting college).

    NCT04460677
    Conditions
    1. Psychological Distress
    2. Stress, Psychological
    3. Autism Spectrum Disorder
    Interventions
    1. Behavioral: Emotional Support Plan
    2. Behavioral: Daily Monitoring
    MeSH:Autistic Disorder Autism Spectrum D Autism Spectrum Disorder Child Development Disorders, Pervasive Stress, Psychological
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more distress.

    Measure: Decreased distress on Patient Health Questionnaire (PHQ-9)

    Time: 8 week study period

    Description: EMA (Ecological Momentary Assessment) reports of decreased distress (in ESP + daily monitoring group only). Higher scores on the item equal higher levels of distress.

    Measure: Decreased distress on EMA reports

    Time: 8 week study period

    Description: The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more anxiety.

    Measure: Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)

    Time: 8 week study period

    Secondary Outcomes

    Description: The ASR is a measure of adaptive functioning and psychopathology (e.g., anxiety, depression symptoms). Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.

    Measure: Adult Self Report (ASR)

    Time: 8 week study period
    10 A Randomized, Investigator- /Subject-blind, Single- and Multiple-ascending Dose, Placebo-controlled Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 Following Oral Administration in Healthy Male Participants

    This study will evaulate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses (SAD and MAD) and food effect (FE) of RO6953958 following oral administration in healthy male participants.

    NCT04475848
    Conditions
    1. Autistic Disorder
    2. Autism Spectrum Disorder
    3. Child Development Disorders, Pervasive
    4. Mental Disorders
    5. Neurodevelopmental Disorders
    Interventions
    1. Drug: RO6953958
    2. Drug: Placebo
    MeSH:Disease Autism Spectrum Disorder Child Development Disorders, Pervasive Mental Disorders Autistic Disorder Neurodevelopmental Disorders Developmental Disabilities
    HPO:Autism Autistic behavior

    Primary Outcomes

    Measure: Percentage of Participants with Adverse Events in Part 1

    Time: From randomization up to 7 weeks (or up to 14 weeks if the participant is part of the food effect cohort)

    Measure: Percentage of Participants with Adverse Events in Part 2

    Time: From randomization up to 8 weeks

    Measure: Part 2: Change in suicide risk assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time: From randomization up to 8 weeks

    Secondary Outcomes

    Measure: Part 1: Maximum Observed Plasma Concentration (Cmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1

    Measure: Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1

    Measure: Part 1: Last Quantifiable Concentration (Clast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Time To the Last Quantifiable Concentration (Tlast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Terminal Elimination Phase Half-Life (T1/2) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Area Under the Concentration-Time Curve from Time 0 to 12 hours (AUC(0-12h)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Apparent Clearance (CL/F) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Apparent Volume of Distribution (V/F) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Cumulative Amount of Unchanged Drug Excreted into the Urine (Ae) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Fraction of the Administered Drug Excreted into the Urine (Fe) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Renal Clearance of the Drug from Urine (CLR) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Parts 2: Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 and Day 10

    Measure: Parts 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 and Day 10

    Measure: Parts 2: Average Plasma Concentration (Cavg) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Tmax of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 and Day 10

    Measure: Part 2: Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: T1/2 of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: CL/F of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: V/F of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: Ae of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: Fe of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: CLR of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: Trough Plasma Concentration (Ctrough) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Accumulation Ratio based on AUC (Rauc) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Accumulation Ratio Based on Cmax (RCmax) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Accumulation Ratio based on Ctrough (RCtrough) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14
    11 Parent Language Intervention for Autism

    As a result of the COVID-19 pandemic, telecoaching/telepractice models are of urgent importance. Given this, parents in the study will receive parent coaching through weekly video calls. To help us understand the best types of telecoaching, we will offer all participants responsive coaching, with half of the participants receiving an additional opportunity to reflect on their own use of language strategies with a therapist using video feedback and the other half receiving responsive coaching as usual, without video feedback. This information is important in helping us to understand the best way to coach parents using a telepractice model so that parents implement the intervention at high fidelity. Furthermore, we will aim to understand how parent learning style may also influence the implementation of these strategies.

    NCT04501588
    Conditions
    1. Autism Spectrum Disorder
    2. Autism
    Interventions
    1. Behavioral: Responsive training with no video feedback
    2. Behavioral: Responsive training with video feedback
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Mother use of intervention strategies will be measured by transcribing and coding mother behaviors during 12-minute parent-child interactions, using a standard set of toys. The primary dependent variable will be the amount of correct strategy used expressed as a percentage correct. This is the percentage of child communication to which the adult responds correctly (i.e., contingently and within 5 seconds).

    Measure: Parent Use of Language Support Strategies (Mother-child interaction)

    Time: Two months after the start of the study

    Secondary Outcomes

    Description: Parent report of child's expressive vocabulary and prelinguistic communication skills

    Measure: MacArthur-Bates Communicative Development Inventory (MCDI) (Child)

    Time: Two months after the start of the study
    12 Developing and Evaluating a Parent-child Intervention for Intellectually Able Children With Autism Spectrum Disorders: A Feasibility Study

    This study will investigate the acceptability and preliminary effectiveness of training parents to use a structured communication intervention that is aimed towards helping children with autism spectrum disorder (ASD). This intervention has demonstrated benefits for non-autistic children in known areas of difficulty found with autistic individuals. There are currently few evidence-based interventions for school-aged children with ASD who have no other language or intellectual disabilities and are educated in mainstream schools. We will evaluate the benefits of training parents to use a freely available communication technique designed to tackle underlying psychological processes crucial to later development.

    NCT04574206
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Behavioral: Elaborative Reminiscence (ER)
    2. Behavioral: Present Tense Talk (PTT)
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: The number of participants who dropped out of the trial as a percentage of the total number recruited.

    Measure: Trial recruitment feasibility

    Time: 20 weeks post-trial

    Description: Percentage of participants who demonstrate 70% or more of intervention behaviours during the training roleplay assessment.

    Measure: Feasibility of training procedures

    Time: Baseline

    Description: Change to caregiver reminiscing style ratio following training

    Measure: Training enactment

    Time: Change from baseline to 20 weeks post-trial

    Description: The actual number of intervention behaviours caregivers demonstrate during conversations at post-trial.

    Measure: Implementation fidelity (actual dosage)

    Time: 20 weeks post-trial

    Description: The mean number of intervention minutes delivered by caregivers

    Measure: Implementation fidelity (frequency of intervention delivery)

    Time: 20 weeks post-trial

    Description: A qualitative analysis (guided by the Theoretical Framework of Acceptability) of post-trial caregiver interviews to determine caregiver acceptability of the ER intervention.

    Measure: Intervention acceptability

    Time: 20 weeks post-trial

    Secondary Outcomes

    Description: Change to child scores on the California Verbal Learning Test for Children (CVLT-C)

    Measure: Memory test

    Time: Change from baseline to 20 weeks post-trial

    Description: Number of child memory elaborations during parent-child conversations

    Measure: Memory elaborations

    Time: Change from baseline to 20 weeks post-trial

    Description: Change to child scores on the Theory of Mind Battery

    Measure: Mental state understanding

    Time: Change from baseline to 20 weeks post-trial

    Description: Change to child scores on the Self-Description Questionnaire

    Measure: Self-concept

    Time: Change from baseline to 20 weeks post-trial
    13 Examining the Efficacy of the TEACCH School Transition to Employment and Post-Secondary Education Program

    The objective of this study is to evaluate the TEACCH School Transition to Employment and Post-Secondary Education (T-STEP) Program. Through randomized assignment young adults (18-21 year-old) with ASD will participate in the full T-STEP Program or a counseling only condition. Effectiveness will be assessed by caregiver report (social communication, executive function, employment readiness), self-report (self-determination, coping, depression), and behavioral observation (i.e., a mock employment experience). The long-term impact of this intervention is to promote a more positive quality of life for young adults with high functioning ASD including increased postsecondary education completion, employment, self-determination, and decreased difficulties with coping and depression.

    NCT04612231
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Behavioral: TEACCH School Transition to Employment and Postsecondary Education (T-STEP)
    2. Behavioral: Counseling Services Alone
    MeSH:Autism Spectrum Disorder
    HPO:Autistic behavior

    Primary Outcomes

    Description: The BWAP is a 63-item informant report measure completed by the caregiver that evaluates skills important for job readiness and work performance across four domains: Work Habits/Attitudes, Interpersonal Relations, Cognitive Skills, and Work Performance Skills. T-Scores (27-73) for each domain will be calculated. A lower T-Score indicates more impairment on the given domain.

    Measure: Change in Becker Work Adjustment Profile-2 (BWAP) Scores from Baseline to Post-Intervention

    Time: Baseline, post-intervention (within 4 weeks of completing the 12-week intervention)

    Description: The BRIEF-A is a 75-item informant report questionnaire that assesses a variety of behavioral manifestations of executive function (e.g., Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials) as well as a composite score of executive function. The informant report will be completed by the caregiver. T-Scores of subscales (Inhibit 39-88; Shift 38-84; Emotional Control 39-77; Self-Monitor 37-79; Initiate 36-83; Working Memory 39-90; Plan/Organize 38-83; Task Monitor 38-84; Organization of materials 37-75), Index scores (e.g., Behavioral Regulation 36-85; Metacognition 36-86) and the total score (e.g., Global Executive Composite 35-88) will be calculated. Lower T-Scores indicate higher levels of executive function and a better outcome.

    Measure: Change in Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A) Scores from Baseline to Post-Intervention

    Time: Baseline, post-intervention (within 4 weeks of completing the 12-week intervention)

    Description: An objective behavioral observation measure developed that provides a series of organization, social communication, and emotion regulation presses during a simulated work environment appropriate for students with ASD and average or higher IQ. Two 15-minute employment tasks appropriate to office (e.g., filing, assembly of information folders) and computer data entry (e.g., accounting receipts, entry of evaluations forms) settings are presented. Participants have opportunities for social interaction with co-workers and supervisors, to respond to corrective feedback, and to request assistance. Assessments will be videotaped and coded by a trained research assistant who will be blind to treatment condition. Domain raw scores will be calculated (Emotion Regulation 0-16; Executive Function 0-16; Social Communication 0-22). Lower scores in each domain indicate less impairment and a better outcome.

    Measure: Change in Transition Readiness and Employability Evaluation (TREE) Scores from Baseline to Post-Intervention

    Time: Baseline, post-intervention (within 4 weeks of completing the 12-week intervention)

    Description: The AIR is a 24 item self-report measure, and an 18 item parent report of self-determination including a measure of knowledge and opportunity to modify and engage in events that affect the participant's wants and needs. The AIR's items are rated on a 5-point Likert scale. The Level of Self-Determination total raw score will be calculated for the self-report (0-120) and the parent report (0-90). A higher score indicates higher levels of self-determining behaviors and a better outcome.

    Measure: Change in The American Institutes for Research Self-Determination Scale (AIR) Scores from Baseline to Post-Intervention

    Time: Baseline, post-intervention (within 4 weeks of completing the 12-week intervention)

    Description: The CSE is a 26-item self-report questionnaire completed by the student with ASD that measures an individual's confidence in using coping behaviors when faced with problems or life challenges. The CSE will be used to measure emotion regulation across three raw scored subscales (e.g., problem-focused coping, 0-48; stopping unpleasant emotions and thoughts, 0-36; and getting support from friends and family, 0-20) and the total raw score (0-104). A higher raw score indicates more self-confidence in an individual's ability to use coping behaviors and a better outcome.

    Measure: Change in Coping Self-Efficacy Scale (CES) Scores from Baseline to Post-Intervention

    Time: Baseline, post-intervention (within 4 weeks of completing the 12-week intervention)

    Secondary Outcomes

    Description: The 20-item self-report version of the CESD-R, completed by the student with ASD, will be used to assess symptoms of depression. Respondents are asked to answer each question using a 4-point Likert scale from "less than one day" to "5-7 days" to describe their feelings (e.g., "I felt sad.") during the past week. The Total CESD-R Score will be calculated as a sum of responses to all 20 questions (0-60). A lower score indicates less depressive symptoms and a better outcome. Assessed at Baseline, post-intervention, and 4 month follow up.

    Measure: Change in Center for Epidemiological Studies - Depression, Revised (CESD-R) Scores

    Time: Up to 28 weeks

    Description: A 20-item self-report completed by the student with ASD used to assess symptoms of anxiety. Respondents are asked to answer each question using a 4-point Likert scale from "almost never" to "almost always." The total score (20-80) will be used as a moderator of intervention efficacy and as an immediate outcome. A low score indicates less impairment of general anxiety and a better outcome. Assessed at Baseline, post-intervention, and 4 month follow up.

    Measure: Change in State Trait Anxiety Inventory (STAI) Trait Scale Scores

    Time: Up to 28 weeks

    Description: The SACQ is a self-report measure completed by the student with ASD of adjustment to college in four areas: Academic Adjustment, Social Adjustment, Personal-Emotional Adjustment, and Institutional Attachment. T-Scores will be calculated for the four domains and the total score (25-75). Conversion tables are categorized by gender and year in college. Higher scores indicates better adjustment to college and a better outcome.

    Measure: Student Adaptation to College Questionnaire (SACQ)

    Time: 4 month post-intervention completion follow up

    Description: GPA will be collected to measure change in success following completion of the intervention. Better outcomes are indicated by increased GPA.

    Measure: Change in Grade Point Average (GPA)

    Time: Baseline, 4 month post-intervention completion follow up, a total of up to 28 weeks

    Description: Employment status will be measured through quantitative categorizations of employment wages (e.g., under minimum wage, minimum wage, above minimum wage, unpaid volunteer; 1-4) and number of hours worked per week (e.g., less than 5 hours, 5-9 hours, 10-19 hours, 20-29 hours, 30-29 hours, 40 hours; 1-6). Maintenance or increase of employment wages and number of hours worked per week is a better outcome.

    Measure: Change in Employment Status Categorizations

    Time: Baseline, 4 month post-intervention completion follow up, a total of up to 28 weeks

    Description: The BWAP is a 63-item informant report measure completed by the caregiver that evaluates skills important for job readiness and work performance across four domains: Work Habits/Attitudes, Interpersonal Relations, Cognitive Skills, and Work Performance Skills. T-Scores (27-73) for each domain will be calculated. A lower T-Score indicates more impairment on the given domain.

    Measure: Change in Becker Work Adjustment Profile-2 (BWAP) Scores from Post-Intervention to 4 Month Follow Up

    Time: Post-Intervention (within 4 weeks of completing the 12-week intervention), 4 month post-intervention completion follow up, a total of up to 16 weeks

    Description: The BRIEF-A is a 75-item informant report questionnaire that assesses a variety of behavioral manifestations of executive function (e.g., Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials) as well as a composite score of executive function. The informant report will be completed by the caregiver. T-Scores of subscales (Inhibit 39-88; Shift 38-84; Emotional Control 39-77; Self-Monitor 37-79; Initiate 36-83; Working Memory 39-90; Plan/Organize 38-83; Task Monitor 38-84; Organization of materials 37-75), Index scores (e.g., Behavioral Regulation 36-85; Metacognition 36-86) and the total score (e.g., Global Executive Composite 35-88) will be calculated. Lower T-Scores indicate higher levels of executive function and a better outcome.

    Measure: Change in Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A) Scores from Post-Intervention to 4 Month Follow Up

    Time: Post-Intervention (within 4 weeks of completing the 12-week intervention), 4 month post-intervention completion follow up, a total of up to 16 weeks

    Description: The AIR is a 24 item self-report measure, and an 18 item parent report of self-determination including a measure of knowledge and opportunity to modify and engage in events that affect the participant's wants and needs. The AIR's items are rated on a 5-point Likert scale. The Level of Self-Determination total raw score will be calculated for the self-report (0-120) and the parent report (0-90). A higher score indicates higher levels of self-determining behaviors and a better outcome.

    Measure: Change in The American Institutes for Research Self-Determination Scale (AIR) Scores from Post-Intervention to 4 Month Follow Up

    Time: Post-Intervention (within 4 weeks of completing the 12-week intervention), 4 month post-intervention completion follow up, a total of up to 16 weeks

    Description: The CSE is a 26-item self-report questionnaire completed by the student with ASD that measures an individual's confidence in using coping behaviors when faced with problems or life challenges. The CSE will be used to measure emotion regulation across three raw scored subscales (e.g., problem-focused coping, 0-48; stopping unpleasant emotions and thoughts, 0-36; and getting support from friends and family, 0-20) and the total raw score (0-104). A higher raw score indicates more self-confidence in an individual's ability to use coping behaviors and a better outcome.

    Measure: Change in Coping Self-Efficacy Scale (CES) Scores from Post-Intervention to 4 Month Follow Up

    Time: Post-Intervention (within 4 weeks of completing the 12-week intervention), 4 month post-intervention completion follow up, a total of up to 16 weeks
    14 Fit Families Program: Fundamental Motor Skill Intervention in Children With Autism Spectrum Disorders and Their Parents

    The investigators aim to identify the effect of a 12-week fundamental motor skills (FMS) (e.g., throwing, catching, running) intervention on the active participation in physical recreation activities and a variety of other factors (child behaviors, communication, and adaptive skills) and to identify patterns, benefits, constraints, and strategies to active participation in physical recreation activities among families of children with autism spectrum disorders (ASD) (pre-post) through in-person or via phone interviews with parents and children with ASD.

    NCT04612647
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Other: 12-week FMS Intervention
    2. Behavioral: Physical Activities & Activity Booklets
    MeSH:Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: The Test of Gross Motor Development - second edition (TGMD-3) is a measure of fundamental motor skills. The total possible range of scores is 47-158, where higher scores are indicative of improved gross motor development.

    Measure: Change in Gross Motor Development as Measured by TGMD-3

    Time: Baseline, 3 week post intervention (15 weeks), 3 months post intervention (24 weeks)

    Description: Children will participate in one-on-one semi-structured interviews with the research team to explore their perception regarding communication strategies (between parent and child), patterns of physical recreation, perceived benefits, and constraints.

    Measure: Number of Participants Whose Perceptions Qualitatively Improve as measured via semi-structured interview

    Time: baseline (approximately 2 weeks prior to intervention), post intervention (12 weeks), follow up (24 weeks)

    Description: Fidelity checklists will be used to determine the fidelity of the intervention. Parents will be asked to email a video of 1-2 lessons per week along with a completed task analysis checklist. Parents will be asked to confirm whether or not each task was completed on the checklist. The research team will complete the same form while viewing the video to ensure whether the parent knows and is implementing the steps intended and if there are fidelity differences between the workshop and home-based group.

    Measure: Fidelity of Intervention reported as Number of Parents who Implements the Intervention as Intended

    Time: up to 12 weeks

    Description: The SCQ is a 40-item survey where each question is a 'yes' or 'no' answer. The total possible range of scores is 0-39 (verbal children) or 0-33 (non-verbal children) with higher scores indicative of greater frequency of symptoms.

    Measure: Change in Social Communication Questionnaire (SCQ)

    Time: baseline (approximately 2 weeks prior to intervention), post intervention (12 weeks)

    HPO Nodes


    HP:0000729: Autistic behavior
    Genes 638
    LMAN2L WFS1 KCNA2 TRIO POGZ CAMTA1 SLC25A22 PIGP NDUFS6 GPHN MID2 LSS SHANK3 LINS1 ZNF41 TBC1D23 RAB39B LIMK1 CNKSR2 SCN8A UBTF EXT2 USP27X EEF1A2 GRIN1 NR2F1 STXBP1 ACTL6B CRADD PIGO GP1BB ALG13 MTOR EGF C12ORF4 TAF1 PRKAR1A SEC24C CHD2 SYNJ1 SYT1 NOVA2 ATP1A3 CACNA1C DMD NUS1 ZBTB20 CRBN WFS1 RLIM FRMPD4 WWOX DLL1 PRKN DEAF1 FTSJ1 HCFC1 SOX2 RPS23 TM4SF20 LRRK2 MECP2 ELN PPP2R5D SCN1B DNAJC6 CXORF56 AFF2 TCF20 JMJD1C MAN1B1 UFD1 ZMIZ1 CREBBP FBXW11 C9ORF72 HECW2 ZFPM2 HNRNPH2 CHRNA7 TSC1 AHDC1 GTF2I TUBB3 NECAP1 FTSJ1 SYNGAP1 C12ORF4 NSD1 SNX14 GABRB2 SATB2 NDUFA1 NDUFA11 FOXG1 STS CXORF56 RORA NDUFAF4 SETD5 GABRA2 HERC1 MSTO1 SYN1 SDHC NAGA GABRD TCF4 HERC2 MED12 NLGN1 TRAK1 CHMP2B OTX2 USP9X TLK2 AUTS2 SCN3A JAM2 OTUD6B BCOR CDH15 PWAR1 PUF60 MECP2 GRIA2 MBOAT7 NEUROD2 GATM GFM1 CUX2 CYFIP2 CACNA1B POMT1 KMT2A SCN2A NAA15 SQSTM1 RAD21 MECP2 POU3F3 DDX6 TREM2 ZIC1 PIGG RIMS2 HIVEP2 SBDS PTCHD1 DYM NPAP1 RERE TANC2 KLLN ARNT2 KDM5B SLC13A5 NDUFAF3 SLC6A8 SNORD116-1 NDUFS4 ARHGEF6 CARS2 MAP1B GABRA5 MED13L GDI1 WDFY3 IARS1 SVBP DCX STXBP1 YY1 CHD1 PCDH19 DDX3X SCN1A ANKRD11 IFNG RNF135 SYP CREBBP ND3 HERC2 GFM2 BCORL1 SLC9A6 NIPBL MKRN3 SNORD115-1 TCF12 CDKL5 TMEM126B NDP ACOX1 CASK GAMT NDUFAF1 NAA10 TSC1 DEAF1 SLC6A1 TBCK TSPAN7 FMR1 NLGN3 WAC GRIN2D SCN8A PSMD12 DNM1 EXTL3 ADSL SLC35A3 PRODH NSUN2 B3GALNT2 RAI1 EZR MED12 NDUFA6 CDKL5 RERE ALMS1 STXBP1 HDAC8 KMT2E TIMMDC1 ALDH18A1 DCPS ASH1L TWNK PUF60 AUTS2 GRIA3 GABRG2 GJA8 CNNM2 CHD2 ST3GAL3 DOCK3 USP7 PROKR2 TMEM231 PIK3CA ARV1 STXBP1 SON CNTNAP2 FMR1 HNF1B PCGF2 SLC1A2 TRMT1 PCDH19 PPP2CA SEC23B GRIA3 SMC1A CLTC PIGP CC2D1A CTCF ALG13 PGAP1 EFL1 TRAPPC9 KCNT1 CEP85L SLC25A12 RSPRY1 MAPK8IP3 ARX AP3B2 SETD2 NTRK2 IQSEC2 RAB11B KCNB1 NDUFB11 HESX1 CNOT3 NEXMIF TECR VCP MFF PGAP3 NDN COG5 DYRK1A BCKDK MECP2 ND2 FLCN PTCHD1 PIGQ AKT1 UCHL1 MEIS2 MAPT HCN1 NUBPL TRAPPC4 FRRS1L CTNNB1 GABBR2 KPTN MKRN3-AS1 PIGY TCF4 AARS1 TRRAP PACS1 RPL10 FRMPD4 PARK7 CHD7 LHX1 DOCK7 DHCR7 ZMIZ1 ACSL4 SNRPN PHF21A THOC2 KDM6B AP2M1 NTNG1 GRIK2 NFIB AIMP1 GNAQ DNAJC21 DYRK1A ALG11 SH2B1 CDH2 ANK3 NDUFB3 GABRA1 DLG4 PINK1 PAK3 TCF20 TMEM138 ADNP NRXN1 CDK19 CDKL5 SETD2 NDUFV1 RREB1 MED25 TMEM216 TBR1 NDUFS7 ZNF423 PSEN1 ARVCF NDST1 GALNT2 KMT5B IQSEC2 PGAP2 PIGC CLIP2 SIM1 TBX1 TMLHE SETD5 SYNGAP1 PPP3CA CNTNAP2 EHMT1 SYNJ1 SIM1 SH2B1 FBXO31 BAZ1B RSRC1 ACTL6A NDUFS2 PRSS12 METTL5 PLXND1 UPF3B PIGV SLC25A1 MED13 UGP2 AP1S2 RFC2 TUSC3 AP3B2 CACNA1A POLA1 ND1 PDE4D SCN2A PODXL OPHN1 USP7 ATRX FGF12 EP300 NDUFS3 PIGL NLGN4X NDUFAF2 RSPRY1 SEMA3E ACTL6B SHANK3 SPECC1L DMXL2 ZNF711 SLC35C1 GATAD2B CLCN4 DLG3 MED23 TBR1 TRIM8 OTUD6B MAGEL2 TBC1D24 RPS6KA3 CDK8 GABRA2 PARS2 PPM1D CC2D2A HNMT MED12L MYT1L NDUFS8 SCN1B NDUFAF4 SYNGAP1 MYT1L FOXRED1 SPATA5 KAT6A SMG9 SNRPN SLC6A8 VAMP2 ST3GAL3 NONO ASXL3 EXT2 FOXP2 CLCN4 ZNF462 NHS VPS13C SIN3A NDUFB10 SNCA NDUFS4 UBA5 STS SRP54 MCTP2 PTEN ACADL WASHC4 MAGEL2 NAGA GABRD EP300 SOX3 PTEN FMN2 GRN REV3L GABRG2 KCNAB2 WAC SNX14 PSMD12 CLP1 USF3 NTNG2 GABRB3 UBE3A HDAC4 DHCR7 ADNP TSC2 SDHD HCN1 SKI CLCN4 SCN2A SCN9A CREBBP DHDDS NDUFS1 FOXG1 KCNA1 NEXMIF BPTF RERE MAOA DNM1 COMT NDUFV2 TBX1 SMAD4 AGTPBP1 GTF2IRD1 NEUROD2 STAG2 PACS2 NLGN3 DEPDC5 NUS1 KCNA2 IQSEC1 MED13L NDUFAF8 PAH PIGL UBA5 DALRD3 GABRA5 SLC45A1 GJA5 SCN1A YWHAG SMC3 STAG1 IREB2 TAF1 MAPK10 DPYD NALCN PDE4D SIK1 CNKSR2 PIGW TMEM237 MEF2C KMT2C CDKL5 MED13 AGTR2 TBX2 IPW NDUFAF5 APC2 AP2M1 ALDH5A1 FGFR1 SZT2 CLIP1 CUX2 ALG13 EP300 INTS1 CACNA2D2 IL1RAPL1 MEIS2 TNIK SCN9A METTL23 BCORL1 DYRK1A SLC35A3 TET3 NDUFAF3 EHMT1 SCN1B EP300 ADGRV1 PWRN1 FOXP1 TBX1 HCN1 SIN3A IL1RAPL1 SRP54 MEF2C NDUFA13 CREBBP CHD8 SARS1 GABRG2 EDC3 TSC2 CEP290 SLC9A7 POLA1 ARID1B WDR26 SRY IQSEC2 MICOS13 ATP6V1A SDHB CTCF NTNG1 PNKP NAA10 RARS1 KDM3B POLR2A MECP2 SCN1A KAT8 TBL2 HIRA ZC3H14 NDUFB9 NTRK2 SVBP DMPK STX1B ZNF81 GNB5 PRDM16 TMEM106B CHD2 MAN1B1 MBOAT7 ARX PDE4D SIM1 TANC2 KDM5C HTRA2 ARFGEF2 DPYD GNAO1 NLGN4X FBXW11 SH2B1
    Protein Mutations 1
    S1009A
    SNP 1
    rs6971

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000729: Autistic behavior
    Genes 638
    LMAN2L WFS1 KCNA2 TRIO POGZ CAMTA1 SLC25A22 PIGP NDUFS6 GPHN MID2 LSS SHANK3 LINS1 ZNF41 TBC1D23 RAB39B LIMK1 CNKSR2 SCN8A UBTF EXT2 USP27X EEF1A2 GRIN1 NR2F1 STXBP1 ACTL6B CRADD PIGO GP1BB ALG13 MTOR EGF C12ORF4 TAF1 PRKAR1A SEC24C CHD2 SYNJ1 SYT1 NOVA2 ATP1A3 CACNA1C DMD NUS1 ZBTB20 CRBN WFS1 RLIM FRMPD4 WWOX DLL1 PRKN DEAF1 FTSJ1 HCFC1 SOX2 RPS23 TM4SF20 LRRK2 MECP2 ELN PPP2R5D SCN1B DNAJC6 CXORF56 AFF2 TCF20 JMJD1C MAN1B1 UFD1 ZMIZ1 CREBBP FBXW11 C9ORF72 HECW2 ZFPM2 HNRNPH2 CHRNA7 TSC1 AHDC1 GTF2I TUBB3 NECAP1 FTSJ1 SYNGAP1 C12ORF4 NSD1 SNX14 GABRB2 SATB2 NDUFA1 NDUFA11 FOXG1 STS CXORF56 RORA NDUFAF4 SETD5 GABRA2 HERC1 MSTO1 SYN1 SDHC NAGA GABRD TCF4 HERC2 MED12 NLGN1 TRAK1 CHMP2B OTX2 USP9X TLK2 AUTS2 SCN3A JAM2 OTUD6B BCOR CDH15 PWAR1 PUF60 MECP2 GRIA2 MBOAT7 NEUROD2 GATM GFM1 CUX2 CYFIP2 CACNA1B POMT1 KMT2A SCN2A NAA15 SQSTM1 RAD21 MECP2 POU3F3 DDX6 TREM2 ZIC1 PIGG RIMS2 HIVEP2 SBDS PTCHD1 DYM NPAP1 RERE TANC2 KLLN ARNT2 KDM5B SLC13A5 NDUFAF3 SLC6A8 SNORD116-1 NDUFS4 ARHGEF6 CARS2 MAP1B GABRA5 MED13L GDI1 WDFY3 IARS1 SVBP DCX STXBP1 YY1 CHD1 PCDH19 DDX3X SCN1A ANKRD11 IFNG RNF135 SYP CREBBP ND3 HERC2 GFM2 BCORL1 SLC9A6 NIPBL MKRN3 SNORD115-1 TCF12 CDKL5 TMEM126B NDP ACOX1 CASK GAMT NDUFAF1 NAA10 TSC1 DEAF1 SLC6A1 TBCK TSPAN7 FMR1 NLGN3 WAC GRIN2D SCN8A PSMD12 DNM1 EXTL3 ADSL SLC35A3 PRODH NSUN2 B3GALNT2 RAI1 EZR MED12 NDUFA6 CDKL5 RERE ALMS1 STXBP1 HDAC8 KMT2E TIMMDC1 ALDH18A1 DCPS ASH1L TWNK PUF60 AUTS2 GRIA3 GABRG2 GJA8 CNNM2 CHD2 ST3GAL3 DOCK3 USP7 PROKR2 TMEM231 PIK3CA ARV1 STXBP1 SON CNTNAP2 FMR1 HNF1B PCGF2 SLC1A2 TRMT1 PCDH19 PPP2CA SEC23B GRIA3 SMC1A CLTC PIGP CC2D1A CTCF ALG13 PGAP1 EFL1 TRAPPC9 KCNT1 CEP85L SLC25A12 RSPRY1 MAPK8IP3 ARX AP3B2 SETD2 NTRK2 IQSEC2 RAB11B KCNB1 NDUFB11 HESX1 CNOT3 NEXMIF TECR VCP MFF PGAP3 NDN COG5 DYRK1A BCKDK MECP2 ND2 FLCN PTCHD1 PIGQ AKT1 UCHL1 MEIS2 MAPT HCN1 NUBPL TRAPPC4 FRRS1L CTNNB1 GABBR2 KPTN MKRN3-AS1 PIGY TCF4 AARS1 TRRAP PACS1 RPL10 FRMPD4 PARK7 CHD7 LHX1 DOCK7 DHCR7 ZMIZ1 ACSL4 SNRPN PHF21A THOC2 KDM6B AP2M1 NTNG1 GRIK2 NFIB AIMP1 GNAQ DNAJC21 DYRK1A ALG11 SH2B1 CDH2 ANK3 NDUFB3 GABRA1 DLG4 PINK1 PAK3 TCF20 TMEM138 ADNP NRXN1 CDK19 CDKL5 SETD2 NDUFV1 RREB1 MED25 TMEM216 TBR1 NDUFS7 ZNF423 PSEN1 ARVCF NDST1 GALNT2 KMT5B IQSEC2 PGAP2 PIGC CLIP2 SIM1 TBX1 TMLHE SETD5 SYNGAP1 PPP3CA CNTNAP2 EHMT1 SYNJ1 SIM1 SH2B1 FBXO31 BAZ1B RSRC1 ACTL6A NDUFS2 PRSS12 METTL5 PLXND1 UPF3B PIGV SLC25A1 MED13 UGP2 AP1S2 RFC2 TUSC3 AP3B2 CACNA1A POLA1 ND1 PDE4D SCN2A PODXL OPHN1 USP7 ATRX FGF12 EP300 NDUFS3 PIGL NLGN4X NDUFAF2 RSPRY1 SEMA3E ACTL6B SHANK3 SPECC1L DMXL2 ZNF711 SLC35C1 GATAD2B CLCN4 DLG3 MED23 TBR1 TRIM8 OTUD6B MAGEL2 TBC1D24 RPS6KA3 CDK8 GABRA2 PARS2 PPM1D CC2D2A HNMT MED12L MYT1L NDUFS8 SCN1B NDUFAF4 SYNGAP1 MYT1L FOXRED1 SPATA5 KAT6A SMG9 SNRPN SLC6A8 VAMP2 ST3GAL3 NONO ASXL3 EXT2 FOXP2 CLCN4 ZNF462 NHS VPS13C SIN3A NDUFB10 SNCA NDUFS4 UBA5 STS SRP54 MCTP2 PTEN ACADL WASHC4 MAGEL2 NAGA GABRD EP300 SOX3 PTEN FMN2 GRN REV3L GABRG2 KCNAB2 WAC SNX14 PSMD12 CLP1 USF3 NTNG2 GABRB3 UBE3A HDAC4 DHCR7 ADNP TSC2 SDHD HCN1 SKI CLCN4 SCN2A SCN9A CREBBP DHDDS NDUFS1 FOXG1 KCNA1 NEXMIF BPTF RERE MAOA DNM1 COMT NDUFV2 TBX1 SMAD4 AGTPBP1 GTF2IRD1 NEUROD2 STAG2 PACS2 NLGN3 DEPDC5 NUS1 KCNA2 IQSEC1 MED13L NDUFAF8 PAH PIGL UBA5 DALRD3 GABRA5 SLC45A1 GJA5 SCN1A YWHAG SMC3 STAG1 IREB2 TAF1 MAPK10 DPYD NALCN PDE4D SIK1 CNKSR2 PIGW TMEM237 MEF2C KMT2C CDKL5 MED13 AGTR2 TBX2 IPW NDUFAF5 APC2 AP2M1 ALDH5A1 FGFR1 SZT2 CLIP1 CUX2 ALG13 EP300 INTS1 CACNA2D2 IL1RAPL1 MEIS2 TNIK SCN9A METTL23 BCORL1 DYRK1A SLC35A3 TET3 NDUFAF3 EHMT1 SCN1B EP300 ADGRV1 PWRN1 FOXP1 TBX1 HCN1 SIN3A IL1RAPL1 SRP54 MEF2C NDUFA13 CREBBP CHD8 SARS1 GABRG2 EDC3 TSC2 CEP290 SLC9A7 POLA1 ARID1B WDR26 SRY IQSEC2 MICOS13 ATP6V1A SDHB CTCF NTNG1 PNKP NAA10 RARS1 KDM3B POLR2A MECP2 SCN1A KAT8 TBL2 HIRA ZC3H14 NDUFB9 NTRK2 SVBP DMPK STX1B ZNF81 GNB5 PRDM16 TMEM106B CHD2 MAN1B1 MBOAT7 ARX PDE4D SIM1 TANC2 KDM5C HTRA2 ARFGEF2 DPYD GNAO1 NLGN4X FBXW11 SH2B1
    Protein Mutations 1
    S1009A
    SNP 1
    rs6971

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook